Junshi Signs an Exclusive License and Commercialization Agreement with Hikma for Toripalimab in Middle East and North Africa Region
Shots:
- Junshi to receive ~$12M up front & 20% royalties of the toripalimab’s net sales in the region. Hikma to get an exclusive license to develop & commercialize toripalimab in all MENA markets & will also obtain the right of the first negotiation for the future commercialization of three under-development drugs in MENA
- Hikma also obtains the rights to commercialize any combination product that comprises any therapeutically active pharmaceutical agent co-formulated or co-packaged with toripalimab
- The agreement helps to accelerate Hikma’s biotech & oncology portfolio and also enables to increase in patients’ access to PD-1s. Toripalimab is an anti-PD-1 mAb that has been approved for marketing in China for 6 indications
Ref: Globenewswire | Image: Junshi
Related News:- Junshi Reports MAA Submission of Toripalimab to the EMA for Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
